Lung Ultrasound for COVID-19 Initial Triage and Monitoring
QUICK
Use of Lung Ultrasound for COVID-19 Patient's Initial Triage Assessment and Early Monitoring: a Pilot Study
2 other identifiers
observational
25
1 country
1
Brief Summary
The QUICK study main aim is to assess the predictive value at Day 1, of a model built on lung ultrasound (LUS) and clinical data, both recorded at hospital admission of COVID-19 patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 27, 2020
CompletedFirst Submitted
Initial submission to the registry
July 7, 2020
CompletedFirst Posted
Study publicly available on registry
July 16, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 7, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 7, 2021
CompletedJune 1, 2021
May 1, 2021
9 months
July 7, 2020
May 28, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Area Under the Curve (AUC) of a predictive model built on LUS and clinical (Q-SOFA, SpiO2/FiO2) data
Area Under the Curve (AUC) of a predictive model at 24h from hospital admission (Favorable vs Unfavorable), built on LUS (12 thoracic regions) and clinical (Q-SOFA, SpiO2/FiO2) data recorded at hospital admission.
Day 1
Secondary Outcomes (2)
Area Under the Curve (AUC) of a predictive model built on CT scan and clinical (Q-SOFA, SpiO2/FiO2) data
Day 1
mortality
Day 28
Study Arms (1)
COVID-19 patients
Adult (\> 18 years) with Proven COVID-19 (specific PCR from respiratory track sample)
Interventions
Patients will be recruited the day of their hospital admission. All patients will be assessed by thoracic Computed Tomography scan then immediately before/after CT scan, patients will be clinically assessed (Q-SOFA, SpiO2/FiO2) and a lung ultrasound evaluation (mean time of evaluation 7 min +/- 3 min; fully respect of COVID-19 barrier measures) will be performed by an investigator. Patients clinical status and outcomes will be extracted from patient's medical file at day 1 and day 28 from patient's admission by investigators blinded from previously recorded lung ultrasound data.
Eligibility Criteria
Pilot study
You may qualify if:
- Adult (\> 18 years).
- Proven COVID-19 (specific PCR from respiratory track sample)
- CT scan prescribed by physician in charge, independently of research.
- Patients consent (or surrogate decision maker's consent in case of need).
You may not qualify if:
- Reduction or cessation of active treatment.
- Patient under guardianship, tutelage measure or judicial protection
- Patient deprived of liberty by judicial order
- No French health insurance.
- Pregnancy or nursing woman.
- Enrolled in another trial evaluating thoracic imaging.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Toulouse
Toulouse, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamine SARTON, ph
University Hospital, Toulouse
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 7, 2020
First Posted
July 16, 2020
Study Start
May 27, 2020
Primary Completion
March 7, 2021
Study Completion
March 7, 2021
Last Updated
June 1, 2021
Record last verified: 2021-05